海南医学
海南醫學
해남의학
HAINAN MEDICAL JOURNAL
2015年
15期
2209-2211
,共3页
马磊%马雯%陈文晟%胡晓晔%刘晓燕%刘美媛%邹青峰
馬磊%馬雯%陳文晟%鬍曉曄%劉曉燕%劉美媛%鄒青峰
마뢰%마문%진문성%호효엽%류효연%류미원%추청봉
胃癌%药物疗法%曲妥珠单抗%多西他赛
胃癌%藥物療法%麯妥珠單抗%多西他賽
위암%약물요법%곡타주단항%다서타새
Gastric cancer%Drug therapy%Trastuzumab%Docetaxel
目的:评价曲妥珠单抗联合多西他赛/S-1二线治疗人类表皮生长因子受体2(HER2)阳性胃癌的临床疗效。方法选取17例既往治疗失败且具有HER-2过表达的晚期胃癌患者。多西他赛40 mg/m2,d1;每3周重复。S-1剂量按照体表面积(BSA)计算给予,BSA<1.25 m2为80 mg/d;1.25≤BSA<1.5 m2为100 mg/d;BSA≥1.5 m2为120 mg/d;d1~14;每3周重复。曲妥珠单抗每3周给药,首日给予负荷剂量8 mg/kg,然后6 mg/kg,每三周重复。两个周期后评价疗效及对生存质量的影响。结果17例患者中CR 1例,PR 7例,SD 6例,PD 3例,总有效率为47.06%。常见不良反应为食欲下降11例、乏力10例和粒细胞减少9例,没有严重不良反应发生。治疗后生存质量评分得到明显提升。结论曲妥珠单抗联合多西他赛/S-1作为二线治疗HER2阳性的进展期胃癌疗效令人满意,不良反应少,值得进一步研究。
目的:評價麯妥珠單抗聯閤多西他賽/S-1二線治療人類錶皮生長因子受體2(HER2)暘性胃癌的臨床療效。方法選取17例既往治療失敗且具有HER-2過錶達的晚期胃癌患者。多西他賽40 mg/m2,d1;每3週重複。S-1劑量按照體錶麵積(BSA)計算給予,BSA<1.25 m2為80 mg/d;1.25≤BSA<1.5 m2為100 mg/d;BSA≥1.5 m2為120 mg/d;d1~14;每3週重複。麯妥珠單抗每3週給藥,首日給予負荷劑量8 mg/kg,然後6 mg/kg,每三週重複。兩箇週期後評價療效及對生存質量的影響。結果17例患者中CR 1例,PR 7例,SD 6例,PD 3例,總有效率為47.06%。常見不良反應為食欲下降11例、乏力10例和粒細胞減少9例,沒有嚴重不良反應髮生。治療後生存質量評分得到明顯提升。結論麯妥珠單抗聯閤多西他賽/S-1作為二線治療HER2暘性的進展期胃癌療效令人滿意,不良反應少,值得進一步研究。
목적:평개곡타주단항연합다서타새/S-1이선치료인류표피생장인자수체2(HER2)양성위암적림상료효。방법선취17례기왕치료실패차구유HER-2과표체적만기위암환자。다서타새40 mg/m2,d1;매3주중복。S-1제량안조체표면적(BSA)계산급여,BSA<1.25 m2위80 mg/d;1.25≤BSA<1.5 m2위100 mg/d;BSA≥1.5 m2위120 mg/d;d1~14;매3주중복。곡타주단항매3주급약,수일급여부하제량8 mg/kg,연후6 mg/kg,매삼주중복。량개주기후평개료효급대생존질량적영향。결과17례환자중CR 1례,PR 7례,SD 6례,PD 3례,총유효솔위47.06%。상견불량반응위식욕하강11례、핍력10례화립세포감소9례,몰유엄중불량반응발생。치료후생존질량평분득도명현제승。결론곡타주단항연합다서타새/S-1작위이선치료HER2양성적진전기위암료효령인만의,불량반응소,치득진일보연구。
Objective To evaluate the effect and toxicity of trastuzumab plus docetaxel/s-1 in the treatment of pretreated Her-2 positive gastric cancer. Methods Seventeen pretreated patients of advanced gastric cancers were enrolled in this study. Trastuzumab was administrated at 8 mg/kg as a loading dose followed by 6 mg/kg every 21 days. Docetaxel 40 mg/m2 was given on day 1 and oral S-1 on days 1~14 of a 21 day cycle. The daily dose of S-1 was as-signed according to body surface area as follows:BSA<1.25 m2, 80 mg/d;1.25≤BSA<1.5 m2, 100 mg/d;BSA≥1.5 m2, 120 mg/d. All enrolled patients received at least two cycles of treatment. Results Among the 17 cases, there were one case of complete response (CR), seven cases of partial response (PR), 6 cases of stable disease (SD), and 3 cases of progression disease (PD), with an overall response rate of 47.06%. Most common adverse reactions were decreased appetite (11 cases), fatigue (10 cases), leucopenia (9 cases). No serious adverse reactions occurred. The quality of life was improved significantly after treatment. Conclusion Trastuzumab plus docetaxel/s-1 is effective for pretreated Her-2 positive advanced gastric cancer, with few adverse reactions, and toxicities are well tolerated.